There are several different types of whistleblower claims. The qui tam/False Claims Act whistleblower claims involve allegations that an individual or company knowingly submitted a false claim to the government or knowingly made a false statement to get a false claim paid by the government. These types of claims often include Medicare or Medicaid fraud, or fraud by a defense contractor.
In addition, there are SEC whistleblower claims, where whistleblowers who provide details to the U.S. Securities and Exchange Commission about potential securities law violations, such as violations of the Foreign Corrupt Practices Act, anti-money laundering, and insider trading laws, receive rewards under the SEC’s Whistleblower Program. Related to these types of claim are CFTC whistleblower claims, in which claims of fraud within the commodities markets are filed with the Commodity Futures Tradition Commission under the Dodd-Frank Whistleblower Reward Program.
There are also IRS whistleblower claims, where whistleblowers who provide information about significant tax fraud or other tax violations can receive rewards from the IRS whistleblower program.
Whatever the type of claim, Bienert | Katzman has the knowledge, experience, and dedication to aggressively litigate on behalf of their whistleblower clients to achieve successful results.
In 2017, Bienert | Katzman served as lead counsel in United States of America, et al v. Celgene Corporation, Case No. 2:10-cv-03165-RGK-SS, a qui tam action that resulted in a $280 million settlement – the second largest recovery ever recorded in a non-intervened case brought under the FCA and the largest recovery involving a manufacturer of cancer drugs.
We carefully assess all whistleblower submissions and work with our whistleblower clients in order to craft the strongest case possible before filing suit or submitting to the appropriate federal agency.